Many patients start strong with Joyous, only to find their progress stalls when they reach the maximum allowed dose. Here's what you need to know about the dose cap and what your options are.
Last updated April 21, 2026
Joyous is a telehealth ketamine provider that has built its brand around "low-dose" sublingual ketamine treatment. For many patients, this approach works well in the beginning: the initial dose provides noticeable relief from depression, anxiety, PTSD, and other conditions that ketamine has shown promise in treating.
The problem emerges over time. Joyous imposes a maximum dose ceiling on the ketamine they will prescribe. While the company does not always publicize this limit prominently, patients consistently report hitting a wall somewhere in the range of 75–150mg sublingual. Once you reach that cap, your provider cannot increase your dose further — regardless of whether you still need more to maintain therapeutic benefit.
For patients whose bodies metabolize ketamine quickly, who have developed physiological tolerance, or who simply need a higher dose to achieve adequate symptom relief, this cap effectively ends their progress with Joyous. They are left with a choice: stay on a dose that no longer fully works, or find another provider.
Ketamine is not a one-size-fits-all medication. Decades of clinical research and practice have established that optimal ketamine dosing varies significantly from patient to patient. Several factors contribute to this variability:
Body weight, metabolism, liver enzyme activity, and genetic factors all influence how a patient processes ketamine. Two people of the same weight can require meaningfully different doses to achieve the same therapeutic effect. A rigid dose cap ignores this biological reality.
Pharmacological tolerance to ketamine is well-documented in medical literature. With repeated exposure, the brain's NMDA receptors adapt, and the same dose produces a diminished response over time. This is not a sign of misuse or addiction — it is a normal neurological process. Responsible dose titration, guided by a clinician, is the standard clinical response to tolerance development.
Patients with treatment-resistant depression, severe PTSD, or chronic pain conditions often require higher doses than those with milder symptoms. A dose cap that works for one patient's moderate anxiety may be woefully inadequate for another patient's severe, multi-year depressive episode.
Sublingual ketamine has a bioavailability of roughly 25–35%, meaning only a fraction of the dose reaches the bloodstream. Compare this to IV administration at near-100% bioavailability. A 150mg sublingual dose delivers far less active medication than a clinical IV infusion. Capping sublingual doses at low levels may leave patients well below the therapeutic window that clinical evidence supports.
The following accounts are composites based on commonly reported patient experiences shared in online forums, support groups, and provider reviews. They are not attributed to specific individuals.
"The first three months on Joyous were genuinely life-changing. My depression lifted in a way nothing else had managed in fifteen years. Then around month four, the effect started fading. I asked to go up and was told I was already at their maximum. It was devastating to feel that window closing and be told there was nothing they could do."
Reported experience — patient who plateaued at the dose cap"My anxiety had been completely manageable for the first time in my adult life. When the dose stopped being enough and they couldn't increase it, the anxiety came roaring back. I started having panic attacks again within two weeks. I felt like I'd been given a taste of what normal life could be, then had it pulled away."
Reported experience — patient whose symptoms returned"After hitting the Joyous ceiling, I spent a lot of time researching alternatives. I switched to Kalm Health and my new prescriber immediately understood the situation. They started me at a dose above what Joyous would allow and titrated from there. Within a few weeks I was back to where I'd been at my best. The difference was night and day."
Reported experience — patient who switched to Kalm Health"I went back to my psychiatrist feeling defeated. She was supportive but said she couldn't prescribe ketamine herself. I ended up back on an SSRI that barely takes the edge off. The whole experience left a bad taste — not because Joyous is bad, but because they never told me upfront there was a hard limit on how far they could go."
Reported experience — patient who returned to traditional treatment"I tried Mindbloom after Joyous. The dosing was better and more flexible, but at $399 per guided session it just wasn't sustainable. I was spending over a thousand dollars a month. I eventually found Kalm through a comparison website and the cost dropped to $124 a month with dosing that actually worked for me."
Reported experience — patient who explored multiple providers"I'd been reading comparison articles trying to figure out which provider to switch to after Joyous. A site comparing ketamine providers side-by-side pointed me to Kalm Health. No dose cap, affordable monthly cost, and a prescriber who actually listens. I wish I'd found them first, but I'm glad I found them at all."
Reported experience — patient who found an alternative through research"What frustrated me most was the lack of transparency. When I signed up for Joyous, nothing in the onboarding mentioned a dose ceiling. I only found out it existed when I asked for an increase and was told no. If I'd known upfront, I might have chosen a different provider from the start."
Reported experience — patient concerned about transparencyBased on reported patient experiences from online forums and support groups. Individual results vary. These are composite accounts, not direct quotes from identified individuals.
If your treatment has stalled because of the Joyous dose ceiling, you are not out of options. Here are the most common paths patients take:
Here is how Joyous stacks up against other popular ketamine providers on the factors that matter most to patients who need dose flexibility.
| Feature | Joyous | Kalm Health | Mindbloom | In-Clinic IV |
|---|---|---|---|---|
| Dose Cap | Yes — low ceiling | No cap — individualized | Flexible but variable | No cap — clinical protocol |
| Monthly Cost | ~$129/mo | $124/mo | $399+ per session | $400–$800 per infusion |
| Administration | Sublingual (at home) | Sublingual (at home) | Sublingual (at home) | IV or IM (in clinic) |
| Prescriber Access | Async + scheduled | Direct prescriber access | Guide-led sessions | In-person clinician |
| Dose Adjustments | Limited by cap | Ongoing, no limit | Per session | Per session, protocol-driven |
| Best For | Mild symptoms, low-dose philosophy | Patients needing flexible dosing at an affordable price | Guided experience seekers | Severe, treatment-resistant cases |
| Medication Included | Yes | Yes | Yes | Yes (administered on-site) |
| Insurance Accepted | No | No | No | Rarely / partial |
For most patients who have outgrown the Joyous dose cap, Kalm Health represents the best balance of flexible dosing, affordability, and quality of care. In-clinic IV is an excellent option for those with severe treatment-resistant conditions and the budget to support it.
Joyous limits the maximum dose of sublingual ketamine they will prescribe. While the exact cap may shift, it is generally well below the doses that many in-clinic protocols and other telehealth providers offer. Patients who need higher therapeutic doses to maintain symptom relief are unable to increase beyond this ceiling.
Joyous positions itself as a low-dose ketamine provider. Their treatment philosophy emphasizes frequent micro-to-low doses rather than the higher-dose sessions common in clinical settings. While this approach works well for some patients, it fundamentally limits options for those who require standard or higher therapeutic doses to achieve relief.
Patients have reported the Joyous dose cap falling in the range of roughly 75–150mg sublingual, though this can vary. By comparison, many in-clinic IV infusions use weight-based dosing at 0.5–1mg/kg, and other at-home providers like Kalm Health prescribe doses tailored to individual patient needs without an arbitrary ceiling.
Yes, you can switch providers at any time. Most telehealth ketamine providers, including Kalm Health, accept patients transitioning from other services. You will typically need a new intake evaluation, but your treatment history will help your new provider determine where to start with dosing. There is no medical reason you cannot transition directly.
Yes. Kalm Health is a telehealth ketamine provider that does not impose an arbitrary dose ceiling. Their clinicians work with patients individually to determine the optimal therapeutic dose, adjusting as needed over time. Treatment starts at $124 per month, making it one of the most affordable options for patients who need flexible dosing.
Yes, pharmacological tolerance to ketamine is well-documented in medical literature. Over weeks or months of regular use, many patients require dose adjustments to maintain the same level of symptom relief. This is a normal neurological process, not a sign of misuse. It is one of the primary reasons why fixed dose caps can become problematic for long-term patients.
Kalm Health starts at $124 per month, which includes prescriber visits, medication, and ongoing support. Joyous pricing starts around $129 per month. Mindbloom typically costs $399 or more per guided session. In-clinic infusions run $400–$800 each. Kalm offers the most competitive price point among providers that do not impose a dose cap.
If you've plateaued at Joyous's dose cap, you have several options: ask your Joyous provider if any further adjustment is possible, consult with your personal psychiatrist or physician about alternatives, consider switching to a provider like Kalm Health that offers flexible dosing without a cap, or explore in-clinic ketamine infusion centers. Do not adjust your dose on your own without medical guidance.
Low-dose ketamine can be effective for some patients, particularly in the early stages of treatment. However, clinical research shows a wide range in optimal dosing across patient populations. What provides full relief for one person may be insufficient for another. The most effective approach is personalized dosing guided by an experienced clinician — which is why arbitrary dose caps can be counterproductive for many patients.
All ketamine use carries dose-dependent risks, including dissociation, nausea, elevated blood pressure, and potential for dependence with prolonged use. However, doses within the standard therapeutic range — as prescribed by qualified clinicians — are considered safe for most patients who have been properly screened. The goal is not "more is better" but rather finding the right dose for each individual under proper medical supervision.